<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024024</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02410</org_study_id>
    <secondary_id>AMC-024</secondary_id>
    <secondary_id>CPMC-IRB-13985</secondary_id>
    <secondary_id>CDR0000068885</secondary_id>
    <nct_id>NCT00024024</nct_id>
  </id_info>
  <brief_title>BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma</brief_title>
  <official_title>A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I/II trial to study the effectiveness of BMS-275291 in treating patients who have&#xD;
      HIV-related Kaposi's sarcoma. Drugs such as BMS-275291 may stop the growth of Kaposi's&#xD;
      sarcoma by stopping blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine whether the change in percent of apoptotic cells on tumor biopsies before and&#xD;
      after treatment with BMS-275291 is a valid endpoint in patients with HIV-related Kaposi's&#xD;
      sarcoma.&#xD;
&#xD;
      II. Determine the safety and tolerability of this drug in these patients. III. Determine the&#xD;
      antitumor effects of this drug in these patients. IV. Determine the effect of this drug on&#xD;
      overall quality of life and tumor-specific symptoms in these patients.&#xD;
&#xD;
      V. Determine the effect of this drug on CD4 and CD8 cell counts and percentages and HIV viral&#xD;
      load in these patients.&#xD;
&#xD;
      VI. Determine the effect of this drug on human herpes virus-8 (HHV-8) viral load and&#xD;
      correlate HHV-8 viral burden, tumor stage, and prognosis in these patients.&#xD;
&#xD;
      VII. Determine the peak plasma concentration of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II&#xD;
      dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients&#xD;
      experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical&#xD;
      response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients&#xD;
      are treated at the RPTD.&#xD;
&#xD;
      Quality of life is assessed on day 15 of the first course and then every 28 days thereafter.&#xD;
&#xD;
      Patients are followed for at least 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rebimastat</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed Kaposi's sarcoma (KS) with serologically documented HIV&#xD;
             infection&#xD;
&#xD;
          -  No symptomatic visceral KS requiring cytotoxic therapy unless refractory to or&#xD;
             intolerant of all currently approved agents for visceral KS&#xD;
&#xD;
          -  At least 5 measurable lesions&#xD;
&#xD;
               -  No prior local therapy to any indicator lesion unless clear progression has taken&#xD;
                  place since treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 750/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.0 times upper limit of normal (ULN) (no greater than 3.5&#xD;
             mg/dL if secondary to indinavir therapy provided direct bilirubin normal)&#xD;
&#xD;
          -  AST and ALT no greater than 3 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No acute, active opportunistic infection within the past 14 days except oral thrush or&#xD;
             genital herpes&#xD;
&#xD;
          -  No other serious medical illness within the past 14 days&#xD;
&#xD;
          -  No other malignancy requiring cytotoxic therapy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy for KS and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy for KS and recovered&#xD;
&#xD;
          -  No concurrent systemic chemotherapy for KS&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids except replacement doses&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy for KS and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  All antiretroviral therapy must be at a stable dose for at least the past 4 weeks and&#xD;
             during treatment&#xD;
&#xD;
          -  At least 3 weeks since prior local therapy for KS and recovered&#xD;
&#xD;
          -  At least 3 weeks since prior investigational therapy for KS and recovered&#xD;
&#xD;
          -  At least 14 days since prior acute treatment of infections other than thrush and&#xD;
             genital herpes&#xD;
&#xD;
          -  Recovered from toxic effects of any other prior KS treatment&#xD;
&#xD;
          -  No other concurrent investigational drugs except investigational new drug&#xD;
             (IND)-available antiretroviral agents&#xD;
&#xD;
          -  No other concurrent KS-specific treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Hayden Von Roenn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Brinker BT, Krown SE, Lee JY, Cesarman E, Chadburn A, Kaplan LD, Henry DH, Von Roenn JH. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. doi: 10.1002/cncr.23108.</citation>
    <PMID>18224669</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>August 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

